Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Studying Genes for Barrett's Esophagus in Brothers and Sisters | Unknown status | Esophageal Cancer, Precancerous Condition | Genetic, Genetic, Other, Other, Procedure - comparative genomic hybridization, genetic linkage analysis, laboratory biomarker analysis, questionnaire administration, study of high risk factors | Medical Research Council, Other | N/A - N/A | Observational | RATIONALE: Learning about how often heartburn and other risk factors occur in brothers and sisters and other family members of patients with Barrett's esophagus may help identify other individuals at risk and identify genes for Barrett's esophagus. PURPOSE: This clinical trial is studying genes for Barrett's esophagus in brothers and sisters. | |||
Clinicaltrials.gov | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer | Drug, Other - saracatinib, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth | ||
|
Clinicaltrials.gov | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer | Drug, Procedure, Procedure - dasatinib, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. | ||
|
Clinicaltrials.gov | Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer | Completed | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | Drug, Other - dasatinib, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. | ||
|
Clinicaltrials.gov | Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | Completed | Head and Neck Cancer | Drug, Drug, Drug, Drug, Drug, Genetic, Genetic, Genetic, Genetic, Genetic, Other, Other, Procedure, Procedure, Radiation, Radiation - carboplatin, cisplatin, docetaxel, fluorouracil, lapatinib ditosylate, cytogenetic analysis, fluorescence in situ hybridization, in situ hybridization, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy, fludeoxyglucose F 18, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Other | 18 Years - 120 Years | Phase 1/Phase 2 | Interventional | RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with radiation therapy, with or without lapatinib, before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed or eliminate the need for surgery. PURPOSE: This phase I/II trial is studying the side effects and best dose of combination chemotherapy given together with radiation therapy with or without lapatinib and to see how well it works in treating patients with locally advanced cancer of the larynx or hypopharynx. | ||
|
Clinicaltrials.gov | Talabostat in Treating Patients With Metastatic Kidney Cancer | Withdrawn | Kidney Cancer | Drug, Procedure, Procedure, Procedure, Procedure, Procedure - talabostat mesylate, diagnostic procedure, enzyme inhibitor therapy, flow cytometry, laboratory biomarker analysis, non-specific immune-modulator therapy | University of Nebraska, National Cancer Institute (NCI), Other, NIH | 19 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well talabostat works in treating patients with metastatic kidney cancer. | ||
|
Clinicaltrials.gov | Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | Completed | Multiple Myeloma and Plasma Cell Neoplasm | Biological, Genetic, Genetic, Other - bevacizumab, gene expression analysis, protein expression analysis, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of multiple myeloma by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory multiple myeloma. | ||
|
Clinicaltrials.gov | Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy | Terminated | Brain and Central Nervous System Tumors, Thrombocytopenia | Drug, Genetic, Genetic, Other, Other, Radiation - temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Observational | RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide may help doctors learn how temozolomide works in the body. It may also help doctors learn more about how a patient's genes may affect the risk of developing thrombocytopenia. PURPOSE: This clinical trial is studying the pharmacokinetics in patients with newly diagnosed high-grade glioma receiving temozolomide and radiation therapy. | |||
|
Clinicaltrials.gov | Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery | Terminated | Colorectal Cancer | Dietary Supplement, Dietary Supplement, Other, Other, Other, Procedure - calcium carbonate, cholecalciferol, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy | Roswell Park Cancer Institute, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | N/A | Interventional | RATIONALE: The use of cholecalciferol and calcium carbonate may keep colon cancer from coming back in patients with colon cancer that has been removed by surgery. PURPOSE: This randomized clinical trial is studying two different doses of cholecalciferol to compare how well they work when given together with calcium carbonate in treating patients with colon cancer that has been removed by surgery. | ||
|
Clinicaltrials.gov | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | Completed | Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | Biological, Drug, Other, Other - sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis, immunologic technique | University of Washington, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Colony stimulating factors, such as sargramostim (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing and may also increase the number of immune cells found in bone marrow or peripheral blood and help the immune system recover from the side effects of chemotherapy. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving GM-CSF together with paclitaxel albumin-stabilized nanoparticle formulation may be an effective treatment for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. PURPOSE: This phase II trial is studying how well giving GM-CSF together with paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that did not respond to previous chemotherapy | ||
|
Clinicaltrials.gov | Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease | Unknown status | Graft Versus Host Disease, Infection, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms | Genetic, Other, Other, Other, Procedure, Procedure - polymerase chain reaction, bronchoalveolar lavage, immunoenzyme technique, laboratory biomarker analysis, bronchoscopy, management of therapy complications | St. Bartholomew's Hospital, Other | 18 Years - N/A | N/A | Interventional | RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment. PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosis early in patients at high risk of fungal infection caused by treatment for hematologic cancer or other disease. | ||
|
Clinicaltrials.gov | Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer | Withdrawn | Depression, Fatigue, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders | Genetic, Other, Other, Other, Procedure, Procedure, Procedure - polymorphism analysis, laboratory biomarker analysis, physiologic testing, questionnaire administration, conventional surgery, fatigue assessment and management, psychosocial assessment and care | Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 55 Years | Observational | RATIONALE: Measuring levels of interleukin-6 and depression may help doctors understand the relationship between interleukin-6 and depression. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying depression and interleukin-6 production in patients with ovarian epithelial cancer. | ||
|
Clinicaltrials.gov | Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma | Unknown status | Hereditary Multiple Melanoma, Melanoma (Skin) | Genetic, Genetic, Genetic, Genetic, Other, Procedure, Procedure - gene expression analysis, microarray analysis, molecular genetic technique, mutation analysis, laboratory biomarker analysis, mutation carrier screening, study of high risk factors | Leeds Cancer Centre at St. James's University Hospital, Other | N/A - N/A | Observational | RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying gene mutations in patients with melanoma and in families with a history of hereditary melanoma. | |||
|
Clinicaltrials.gov | Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Completed | Head and Neck Cancer | Drug, Drug, Other, Other - bortezomib, docetaxel, laboratory biomarker analysis, pharmacological study | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with docetaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with docetaxel works in treating patients with recurrent or metastatic head and neck cancer. | ||
|
Clinicaltrials.gov | Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases | Biological, Drug, Genetic, Genetic, Other, Other, Procedure - sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Other, NIH | 18 Years - 120 Years | Phase 2 | Interventional | RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving bexarotene together with GM-CSF may be an effective treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia. PURPOSE: This phase II trial is studying how well giving bexarotene together with GM-CSF works in treating patients with MDS or acute myeloid leukemia. | ||
|
Clinicaltrials.gov | Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma | Completed | Brain and Central Nervous System Tumors | Drug, Genetic, Genetic, Other, Other, Other - sagopilone, fluorescence in situ hybridization, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study | European Organisation for Research and Treatment of Cancer - EORTC, Other | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone ZK-219477 works in treating patients with recurrent glioblastoma. | ||
|
Clinicaltrials.gov | Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer | Completed | Prostate Cancer | Dietary Supplement, Other - lycopene, laboratory biomarker analysis | University of Illinois at Chicago, National Cancer Institute (NCI), Other, NIH | Male | 35 Years - 75 Years | Phase 1 | Interventional | RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of lycopene, a substance found in tomatoes, may keep prostate cancer from forming in patients at high risk of developing prostate cancer. PURPOSE: This phase I trial is studying the side effects and best dose of lycopene in preventing prostate cancer in patients who are at high risk of developing prostate cancer. | |
|
Clinicaltrials.gov | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | Completed | Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma | Drug, Drug, Other, Other - lenalidomide, temsirolimus, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 1 | Interventional | This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temsirolimus may also stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving lenalidomide together with temsirolimus may kill more cancer cells. | ||
|
Clinicaltrials.gov | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Completed | B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Drug, Other, Other - sunitinib malate, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. | ||
|
Clinicaltrials.gov | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | Terminated | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | Drug, Other - saracatinib, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial is studying how well AZD0530 works in treating patients with previously treated metastatic colon cancer or rectal cancer. AZD0530 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
